Daiwa Securities Group Inc. Sells 115 Shares of BioNTech SE (NASDAQ:BNTX)

Daiwa Securities Group Inc. lessened its holdings in shares of BioNTech SE (NASDAQ:BNTX) by 6.0% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,810 shares of the company’s stock after selling 115 shares during the quarter. Daiwa Securities Group Inc.’s holdings in BioNTech were worth $215,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in BNTX. Baillie Gifford & Co. raised its holdings in BioNTech by 0.4% in the 3rd quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company’s stock worth $986,750,000 after purchasing an additional 31,773 shares in the last quarter. Deerfield Management Company L.P. Series C raised its stake in BioNTech by 4.3% in the second quarter. Deerfield Management Company L.P. Series C now owns 594,000 shares of the company’s stock worth $47,734,000 after buying an additional 24,426 shares in the last quarter. Candriam S.C.A. lifted its holdings in BioNTech by 261.2% in the second quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock worth $46,526,000 after buying an additional 418,695 shares during the period. DekaBank Deutsche Girozentrale boosted its position in BioNTech by 12.6% during the 3rd quarter. DekaBank Deutsche Girozentrale now owns 481,397 shares of the company’s stock valued at $56,886,000 after acquiring an additional 53,800 shares in the last quarter. Finally, Point72 Asset Management L.P. grew its holdings in shares of BioNTech by 283.5% during the 2nd quarter. Point72 Asset Management L.P. now owns 461,711 shares of the company’s stock worth $37,103,000 after acquiring an additional 341,311 shares during the period. Institutional investors own 15.52% of the company’s stock.

BioNTech Stock Down 1.9 %

BNTX stock opened at $118.39 on Monday. The stock has a market capitalization of $28.38 billion, a P/E ratio of -56.38 and a beta of 0.26. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. BioNTech SE has a 1-year low of $76.53 and a 1-year high of $131.49. The business has a fifty day moving average price of $113.81 and a 200-day moving average price of $98.73.

BioNTech (NASDAQ:BNTX) last issued its earnings results on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.26) by $2.07. The business had revenue of $1.24 billion during the quarter, compared to analyst estimates of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. BioNTech’s revenue was up 38.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.73 EPS. Equities analysts forecast that BioNTech SE will post -3.72 earnings per share for the current fiscal year.

Analysts Set New Price Targets

BNTX has been the subject of a number of research analyst reports. Berenberg Bank assumed coverage on BioNTech in a research note on Tuesday, November 19th. They issued a “buy” rating and a $130.00 target price for the company. HSBC boosted their target price on shares of BioNTech from $97.00 to $136.00 and gave the company a “buy” rating in a report on Monday, October 7th. Jefferies Financial Group upgraded shares of BioNTech from a “hold” rating to a “buy” rating and increased their price target for the stock from $96.00 to $150.00 in a research note on Tuesday, September 17th. TD Cowen dropped their price objective on shares of BioNTech from $132.00 to $122.00 and set a “hold” rating on the stock in a research note on Tuesday, November 5th. Finally, Morgan Stanley raised shares of BioNTech from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $93.00 to $145.00 in a research note on Tuesday, September 24th. Four analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, BioNTech presently has an average rating of “Moderate Buy” and a consensus target price of $138.67.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.